Aurinia Pharmaceuticals Inc (AUPH)

[biotech_researcher]

Jess, you will like this:

Cowen:" $AUPH CONSULTANT CHECKS STRENGTHEN LT CONVICTION. Clinicians are initially using Lupkynis in second line; clinician feedback has been overwhelmingly positive; benefits vs. other options(Benlysta failures) will lead to substantial 30-40% penetration; $1B+. TP=$50+ on(M&A)"

Cowen:" $AUPH CONSULTANT CHECKS STRENGTHEN LT CONVICTION. Clinicians are initially using Lupkynis in second line; clinician feedback has been overwhelmingly positive; benefits vs. other options(Benlysta failures) will lead to substantial 30-40% penetration; $1B+. TP=$50+ on(M&A)"

— Tom Silver (@TomSilver39) June 14, 2021

Tom Silver is the best